Ibrutinib for bridging to allogeneic hematopoietic stem cell transplantation (alloHCT) in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is safe and effective: Updated results of a study by the EBMT Chronic Malignancy and Lymphoma Working Parties, the French Cooperative Group for CLL, and the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Dreger, P
  • Michallet, M
  • Bosman, P
  • Sobh, M
  • Boumendil, A
  • Nagler, A
  • Scheid, C
  • Cornelissen, J
  • Mueller, L
  • Niederwieser, D
  • Vandenberghe, E
  • Scortechini, I
  • Schoemans, H
  • Andersen, N
  • Finke, J
  • Russo, D
  • Ljungman, P
  • Passweg, J
  • van Gelder, M
  • Durakovic, N
  • Labussiere, H
  • Berg, Tobias
  • Wulf, G
  • Bethge, W
  • Stilgenbauer, S
  • Mordini, N
  • Schaap, M
  • Fox, C
  • Kroeger, N
  • Montoto, S
  • Schetelig, J

publication date

  • July 2017